Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer
(Thomson Reuters ONE) -
Mechelen, Belgium; 17 January 2017 - Galapagos NV (Euronext & NASDAQ: GLPG)
announces the appointment of Dr. Walid Abi-Saab to the role of Chief Medical
Officer, beginning on 1 March 2017.
The Chief Medical Officer will be a member of the Executive Committee and drive
the overall medical strategy of the Company. The CMO has responsibility for late
stage clinical development and operations, medical and regulatory affairs, and
safety. He will be a key participant in the Company's strategic planning,
partnering discussions, and presentations to investors and other stakeholders.
Previously, Walid Abi-Saab was with Shire Pharmaceuticals where he held various
clinical development leadership roles, most recently as Group Vice President,
Global Clinical Development - Therapeutic Area Head, Gastro-intestinal,
Endocrinology and Metabolism. Prior to that, he led clinical development
activities at Novartis, Abbott Laboratories, and Pfizer, addressing a wide range
of therapeutic areas and leading teams throughout the clinical development
process. Under his leadership, more than 30 molecules have advanced through
clinical development leading to several approvals in the US, EU and Canada.
Prior to his pharma roles, Walid was Assistant Professor of Psychiatry and
Neurosurgery at Yale University Medical School, where he headed their
Schizophrenia Research at the Clinical Neuroscience Research Unit and the
Neurosurgery Epilepsy Microdialysis Research Program. Walid holds an MD degree
from Université Saint Joseph in Beirut, Lebanon. He completed a Psychiatry
residency training and a Neuroscience Research Fellowship at Yale University
Medical School in New Haven, Connecticut.
"I am very excited to join Galapagos at this critical and transformative stage.
I have been quite impressed by their tremendous success, as shown by the rich
and maturing pipeline. I look forward to being part of the team that aims to
bring these promising medicines to patients and address their unmet needs," said
Dr. Walid Abi-Saab.
"We welcome Walid to the Galapagos team. With such a large pipeline of clinical
programs and our ambition to deliver one Phase 3 start every other year,
Galapagos is expanding development activities significantly," said Onno van de
Stolpe, CEO. "Walid brings more than 15 years of successful leadership in
developing new medicines. We look to Walid to take the compounds which show
early success in the clinic the rest of the way, and make us a late-stage
development powerhouse."
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2,
Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 480 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Director Communications
Communications +31 6 53 591 999
+1 781 460 1784 communications(at)glpg.com
Paul van der Horst
Director IR & Business
Development
+31 6 53 725 199
ir(at)glpg.com
Forward-Looking Statements
This release may contain forward-looking statements, including statements
regarding any guidance given by Galapagos' management, Galapagos' strategic
ambitions, the anticipated timing of clinical studies with Galapagos' product
candidates, and the progression and results of such studies. Galapagos cautions
the reader that forward-looking statements are not guarantees of future
performance. Forward-looking statements involve known and unknown risks,
uncertainties and other factors which might cause the actual results, financial
condition and liquidity, performance or achievements of Galapagos, or industry
results, to be materially different from any historic or future results,
financial conditions and liquidity, performance or achievements expressed or
implied by such forward-looking statements. In addition, even if Galapagos'
results, performance, financial condition and liquidity, and the development of
the industry in which it operates are consistent with such forward-looking
statements, they may not be predictive of results or developments in future
periods. Among the factors that may result in differences are the inherent
uncertainties associated with competitive developments, clinical trial and
product development activities and regulatory approval requirements (including
that data from the ongoing and planned clinical research programs may not
support registration or further development of Galapagos' product candidates due
to safety, efficacy or other reasons), Galapagos' reliance on collaborations
with third parties, and estimating the commercial potential of Galapagos'
product candidates. A further list and description of these risks, uncertainties
and other risks can be found in Galapagos' Securities and Exchange Commission
(SEC) filings and reports, including in Galapagos' most recent annual report on
form 20-F filed with the SEC and subsequent filings and reports filed by
Galapagos with the SEC. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These forward-
looking statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statement is based or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements, unless
specifically required by law or regulation.
Walid Abi-Saab CMO Galapagos:
http://hugin.info/133350/R/2071835/778589.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.01.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 518226
Anzahl Zeichen: 7669
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 168 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Dr. Walid Abi-Saab joins Galapagos as Chief Medical Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
